Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 3
2007 2
2008 4
2009 5
2010 3
2011 7
2012 9
2013 6
2014 5
2015 4
2016 4
2017 6
2018 1
2019 1
2020 2
2021 2
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Atazanavir pharmacokinetics, efficacy and safety in pregnancy: a systematic review.
Eley T, Bertz R, Hardy H, Burger D. Eley T, et al. Antivir Ther. 2013;18(3):361-75. doi: 10.3851/IMP2473. Epub 2012 Nov 26. Antivir Ther. 2013. PMID: 23676668 Review.
BACKGROUND: For some antiretroviral therapies, drug concentrations are reduced during pregnancy, potentially compromising effective virological suppression. METHODS: Data on atazanavir boosted with ritonavir in pregnancy are reviewed. RESULTS: With standard atazanavir …
BACKGROUND: For some antiretroviral therapies, drug concentrations are reduced during pregnancy, potentially compromising effective virologi …
Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
Johnson DH, Venuto C, Ritchie MD, Morse GD, Daar ES, McLaren PJ, Haas DW. Johnson DH, et al. Pharmacogenet Genomics. 2014 Apr;24(4):195-203. doi: 10.1097/FPC.0000000000000034. Pharmacogenet Genomics. 2014. PMID: 24557078 Free PMC article. Clinical Trial.
METHODS: Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were characterized in HIV-1-infected patients randomized to atazanavir/ritonavir-containing regimens. ...Use of ritonavir as a pharmacokinetic enhancer may have abrogated …
METHODS: Plasma atazanavir pharmacokinetics and indirect bilirubin concentrations were characterized in HIV-1-infected patient …
Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers.
Sekar VJ, Lefebvre E, De Marez T, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, Hoetelmans RM. Sekar VJ, et al. Drugs R D. 2007;8(4):241-8. doi: 10.2165/00126839-200708040-00004. Drugs R D. 2007. PMID: 17596110 Clinical Trial.
BACKGROUND AND OBJECTIVE: To investigate the potential for pharmacokinetic interactions between the protease inhibitors darunavir (DRV, TMC114) coadministered with low-dose ritonavir (darunavir/r), and atazanavir in HIV-negative, healthy volunteers. ...The safety an …
BACKGROUND AND OBJECTIVE: To investigate the potential for pharmacokinetic interactions between the protease inhibitors darunavir (DR …
Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Song I, Borland J, Chen S, Lou Y, Peppercorn A, Wajima T, Min S, Piscitelli SC. Song I, et al. Br J Clin Pharmacol. 2011 Jul;72(1):103-8. doi: 10.1111/j.1365-2125.2011.03947.x. Br J Clin Pharmacol. 2011. PMID: 21342217 Free PMC article. Clinical Trial.
AIMS: S/GSK1349572 is an unboosted, once daily, next generation integrase inhibitor with potent activity, low pharmacokinetic (PK) variability and a novel resistance profile. As the primary route of metabolism is via glucuronidation, the effects of atazanavir (ATV, …
AIMS: S/GSK1349572 is an unboosted, once daily, next generation integrase inhibitor with potent activity, low pharmacokinetic (PK) va …
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naive.
Bertz RJ, Persson A, Chung E, Zhu L, Zhang J, McGrath D, Grasela D. Bertz RJ, et al. Pharmacotherapy. 2013 Mar;33(3):284-94. doi: 10.1002/phar.1205. Pharmacotherapy. 2013. PMID: 23456732 Clinical Trial.
STUDY OBJECTIVE: To investigate the pharmacokinetic and pharmacodynamic relationships of the human immunodeficiency virus (HIV)-protease inhibitor atazanavir (ATV) in the presence and absence of the pharmacokinetic booster ritonavir, utilizing ATV plasma trou …
STUDY OBJECTIVE: To investigate the pharmacokinetic and pharmacodynamic relationships of the human immunodeficiency virus (HIV)-prote …
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, Agarwala S, Dragone J, Bertz R. Zhu L, et al. J Clin Pharmacol. 2011 Mar;51(3):368-77. doi: 10.1177/0091270010367651. Epub 2010 May 10. J Clin Pharmacol. 2011. PMID: 20457590 Clinical Trial.
This study investigated a clinically effective, low dose of omeprazole (20 mg daily) on atazanavir pharmacokinetics in 56 healthy volunteers given atazanavir/ritonavir 300/100 and 400/100 mg once daily. ...This study found that omeprazole 20 mg once daily has …
This study investigated a clinically effective, low dose of omeprazole (20 mg daily) on atazanavir pharmacokinetics in 56 heal …
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Zhu L, Liao S, Child M, Zhang J, Persson A, Sevinsky H, Eley T, Xu X, Krystal M, Farajallah A, McGrath D, Molina JM, Bertz R. Zhu L, et al. J Antimicrob Chemother. 2012 Feb;67(2):465-8. doi: 10.1093/jac/dkr490. Epub 2011 Nov 25. J Antimicrob Chemother. 2012. PMID: 22121190 Clinical Trial.
OBJECTIVES: To characterize the pharmacokinetics and inhibitory quotient (IQ) of atazanavir/ritonavir- and lopinavir/ritonavir-based regimens in HIV-infected, treatment-naive patients. ...A subset of patients participated in an intensive pharmacokinetic evalu …
OBJECTIVES: To characterize the pharmacokinetics and inhibitory quotient (IQ) of atazanavir/ritonavir- and lopinavir/ritonavir …
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
Venuto CS, Mollan K, Ma Q, Daar ES, Sax PE, Fischl M, Collier AC, Smith KY, Tierney C, Morse GD. Venuto CS, et al. J Antimicrob Chemother. 2014 Dec;69(12):3300-10. doi: 10.1093/jac/dku303. Epub 2014 Aug 25. J Antimicrob Chemother. 2014. PMID: 25159623 Free PMC article. Clinical Trial.
OBJECTIVES: It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation to virological failure, safety and tolera …
OBJECTIVES: It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/e …
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Walimbwa SI, Kaboggoza JP, Waitt C, Byakika-Kibwika P, D'Avolio A, Lamorde M. Walimbwa SI, et al. Trials. 2021 Nov 23;22(1):831. doi: 10.1186/s13063-021-05752-1. Trials. 2021. PMID: 34814933 Free PMC article. Clinical Trial.
METHODS: This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B). ...Furthermore, this study will deliver pharmaco …
METHODS: This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions bet …
Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers.
Krishna G, Moton A, Ma L, Martinho M, Seiberling M, McLeod J. Krishna G, et al. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):437-44. doi: 10.1097/qai.0b013e3181acb51b. J Acquir Immune Defic Syndr. 2009. PMID: 19623694 Clinical Trial.
METHODS: A phase 1, open-label, randomized, crossover, drug interaction study was conducted to assess the pharmacokinetic effects of coadministration of posaconazole (400 mg twice daily), with atazanavir (ATV) (300 mg/d alone) and with ritonavir (100 mg/d) or with e …
METHODS: A phase 1, open-label, randomized, crossover, drug interaction study was conducted to assess the pharmacokinetic effects of …
60 results